CClinicalTrials.gg
CompletedNCT05073523Updated Nov 15, 2022

Dietary Biomarkers 2.0: From Potential Towards Implementation.

An interventional study of Diet in Healthy, sponsored by Chalmers University of Technology. Completed at 1 site in Sweden. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-15.

Sponsored by Chalmers University of Technology · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The aim of this project is to fill a gap in the translation of dietary biomarkers as unbiased measures of food intake from high-end academic research into a methodology that ca be easily applied across academic, public and private health sector to objectively assess specific dietary intakes at group and individuals' level to a) improve understanding of diet and health relationships b) address compliance in dietary intervention studies and c) assess individuals' dietary intakes to guide their eating towards improved health. The study will be carried out as a three-way cross-over design with three different meal compositions (A, B, C) where each meal is provided 3 times per day during four days per meal. A wash-out period of 7 days where participants consume their habitual diet is implemented and a 3-day run-in before the study meal intervention. The first day of study meal intervention includes postprandial measurements during 8 hours.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Chalmers University of Technology is the lead sponsor of 18 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Men and women
  • Age 18-80 years
  • Body mass index (BMI) 18.5-30 kg/m2
  • Fasting glucose ≤ 6.1 mmol/l
  • Low density lipoprotein (LDL), Cholesterol ≤ 5.30 mmol/L
  • Triglycerides ≤ 2.60 mmol/L
  • Signed informed consent

Exclusion criteria

Exclusion Criteria:

  • Food allergies or intolerances preventing consumption of any products included in the study.
  • Strict vegetarian or vegan, participants must be able to eat dairy products as it is included in the study diet.
  • Unable to sufficiently understand written and spoken Swedish to provide written consent and understand information and instructions from the study personal.
  • Unable to satisfactorily complete the 3-day weighted food records.
  • Continuous/daily use of medication.
  • Pregnant, lactating or planning a pregnancy during the study period.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Other
    Meal A

    Diet: meal proportion 1

    Other: Diet

  • Other
    Meal B

    Diet: meal proportion 2

    Other: Diet

  • Other
    Meal C

    Diet: meal proportion 3

    Other: Diet

Interventions

  • OtherDiet

    All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.

06

What researchers measure

Primary outcomes

  1. Plasma concentrations of dietary candidate biomarkers (daidzein, genistein, hesperetin, naringenin, phloretin, kaempferol, 2-thiothiazolidine-4-carboxylic acid, sulforaphane)

    Difference in the plasma concentrations of diet specific biomarkers comparing before (baseline) and after intervention meal (average plasma concentration over the 24h period).

    Time frame: 24 hours

  2. Plasma concentrations of dietary biomarker candidates (proline betaine, 4-hydroxyphenylacetic acid, 4-hydroxyphenylpyruvate, indole-3-lactic acid, pipecolic acid, s-methylcysteine, avenacoside-A and avenacoside-B)

    Difference in the plasma concentrations of diet specific biomarkers comparing before (baseline) and after intervention meal (average plasma concentration over the 24 h period).

    Time frame: 24 hours

  3. Plasma concentration-time profile over 24h (AUCs) of dietary biomarker candidates ( daidzein, genistein, hesperetin, naringenin, phloretin, kaempferol, 2-thiothiazolidine-4-carboxylic acid, sulforaphane)

    Differences in plasma AUCs between the three intake levels for each biomarker candidate

    Time frame: 24 hours

  4. Plasma concentration-time profile over 24h (AUCs) of dietary biomarker candidates proline betaine, 4-hydroxyphenylacetic acid, 4-hydroxyphenylpyruvate, indole-3-lactic acid, pipecolic acid, s-methylcysteine, avenacoside-A and avenacoside-B

    Differences in plasma AUCs between the three intake levels.

    Time frame: 24 hours

Secondary outcomes

  1. Gut microbiome

    Fecal samples will analyzed for composition of the gut microbiome, baseline compared with after 4 days of intervention meals.

    Time frame: 4 days

  2. Plasma metabolites

    Untargeted metabolomics will be performed using established methods for plasma. Analyzed exploratorily using untargeted metabolomics to find potential biomarker panels that reflect the specific foods included in study meals. Baseline compared with after intervention meals.

    Time frame: 4 days

  3. Urine metabolites

    Analyzed exploratorily using untargeted metabolomics to find potential biomarker panels that reflect the specific foods included in study meals.

    Time frame: 24 hours

  4. Fecal concentrations of diet specific biomarkers daidzein, genistein, hesperetin, naringenin, phloretin, kaempferol, 2-thiothiazolidine-4-carboxylic acid, sulforaphane

    Evaluate new simple sampling techniques using faecal swabs.

    Time frame: 4 days

  5. Fecal concentrations of diet specific biomarkers proline betaine, 4-hydroxyphenylacetic acid, 4-hydroxyphenylpyruvate, indole-3-lactic acid, pipecolic acid, s-methylcysteine, avenacoside-A and avenacoside-B)

    Evaluate new simple sampling techniques using fecal swabs.

    Time frame: 4 days

  6. Blood concentrations of diet specific biomarkers daidzein, genistein, hesperetin, naringenin, phloretin, kaempferol, 2-thiothiazolidine-4-carboxylic acid, sulforaphane

    Evaluate new simple sampling techniques using dried blood spots.

    Time frame: 4 days

  7. Blood concentrations of diet specific biomarkers proline betaine, 4-hydroxyphenylacetic acid, 4-hydroxyphenylpyruvate, indole-3-lactic acid, pipecolic acid, s-methylcysteine, avenacoside-A and avenacoside-B)

    Evaluate new simple sampling techniques using dried blood spots.

    Time frame: 4 days

  8. Urine concentrations of diet specific biomarkers daidzein, genistein, hesperetin, naringenin, phloretin, kaempferol, 2-thiothiazolidine-4-carboxylic acid, sulforaphane

    Evaluate new simple sampling techniques using dried urine spots.

    Time frame: 4 days

  9. Blood concentrations of diet specific biomarkers proline betaine, 4-hydroxyphenylacetic acid, 4-hydroxyphenylpyruvate, indole-3-lactic acid, pipecolic acid, s-methylcysteine, avenacoside-A and avenacoside-B

    Evaluate new simple sampling techniques using dried urine spots.

    Time frame: 4 days

07

Study locations

1 site
  • University of Gothenburg, Department of Food and Nutrition and Sport Science
    Gothenburg, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05073523
Lead sponsor
Chalmers University of Technology
Responsible party
Rikard Landberg (Professor, Chalmers University of Technology) — Principal investigator
First posted
Oct 11, 2021
Start date
Sep 27, 2021
Primary completion
Oct 28, 2022
Completion
Oct 28, 2022
Last update
Nov 15, 2022

Study contacts

Rikard Landberg, Dr
principal investigator · Chalmers University of Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion